Levi & Korsinsky notifies investors of Santarus, Inc. (“Santarus” or the “Company”) (Nasdaq:SNTS) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Salix Pharmaceuticals, Ltd. (“Salix”) (NasdaqGS:SLXP). Click here to learn more about the case http://zlk.9nl.com/santarus-snts/, or call: 877-363-5972. There is no cost or obligation to you. Salix and Santarus announced on November 7, 2013 that the companies have entered into a definitive merger agreement under which Salix will acquire all of the outstanding common stock of Santarus for approximately $2.6 billion. Under the terms of the transaction, Santarus shareholders will receive $32.00 for each share of Santarus stock they own. The investigation concerns whether the Santarus Board of Directors breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Salix Pharmaceuticals, Inc. is underpaying for Santarus shares. If you own Santarus common stock and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/santarus-snts/. Levi & Korsinsky is a national firm with offices in New York, New Jersey, Stamford, Connecticut and Washington D.C. The firm's 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.